One name that's quickly moving within range of triggering a near-term breakout trade is
(MACK - Get Report)
, a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit by the sellers during the last six months, with shares off by 21%.
If you look at the chart for Merrimack Pharmaceuticals, you'll notice that this stock has been trending inside of a tight consolidation pattern for the last three months, with shares moving between $5.91 on the downside and $6.93 on the upside. Shares of MACK have now started to flirt with its 50-day moving average of $6.26 a share and it's quickly moving within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance levels at $6.48 to $6.66 a share and then once it takes out more resistance at $6.93 to its 200-day moving average at $7.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 352,520 shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take its next major overhead resistance levels at $7.50 to $8 a share
Keep in mind that MACK is set to report earnings on Thursday, March 14 before the market open. This potential breakout trade could either trigger after or before MACK's earnings date, so plan your trade accordingly if it triggers soon.
Traders can look to buy MACK off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support levels at $6.05 to $5.91 share. One can also buy MACK off strength once it clears those breakout levels with volume and then simply use a stop that sits right below its 50-day at $6.26 a share.